Telomir Pharmaceuticals, Inc.
TELONasdaq
$1.11
↓ -6.7%Jul 17 close · end-of-day
Price
1Y↓ -3.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$38.2M
Enterprise Value
$38.2M
P/E
—
P/S
—
P/B
7.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$9.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-185.9%
ROIC
—
Debt / Equity
—
Net Cash
—
Return 1Y
-8.3%
Company profile
We are a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Our corporate headquarters is located at 855 N Wolfe Street, Suite 601, Baltimore, Maryland.
- CEO
- Christopher Chapman, Jr.
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Florida
- Website
- telomirpharma.com
Earnings
TELO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.03↓ -57.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | -$854,147.00 | -$13.1M | -$16.5M | -$10.4M |
| Diluted EPS | -$0.03 | $0.48 | -$0.56 | -$0.33 |
| Operating cash flow | -$468,661.00 | -$3.9M | -$5.1M | -$3.7M |
| Free cash flow | — | — | — | — |
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| Net margin | — | — | — | — |
| Line item | Q3 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | $2.2M | — | — | — | — |
| Net income | -$1.4M | -$6.0M | -$2.9M | -$2.2M | -$5.1M | -$1.1M | -$2.1M | -$990,947.00 |
| Diluted EPS | $0.05 | -$0.20 | -$0.18 | -$0.07 | $0.17 | -$0.03 | -$0.40 | -$0.03 |
| Operating cash flow | -$1.5M | -$1.0M | -$605,808.00 | -$863,132.00 | -$696,445.00 | -$927,264.00 | -$1.2M | -$1.8M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-22 | Aminov Erez· CEO and Chairman | J | 7,319,710 | $1.37 | $10.0M | filing |
Latest 1 transaction.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.